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Good adherence is critical for antiretroviral therapy (ART) in sub-Saharan Africa. We report on the
characteristics of medicine companions (MCs) chosen by Ugandan patients enrolling on ART, and on how
MCs were chosen, and what roles they played. Baseline data on MCs of 1453 participants in a randomized
controlled trial comparing facility and home-based delivery of ART in Jinja, Uganda were analyzed. Textual data
on experience with MCs were collected through in-depth interviews among a subsample of 40 trial participants
equally divided by sex and trial arm. Significantly more women (71%) than men (29%) were recruited. The
majority (75%) of women participants were either widowed (51%) or separated or divorced (24%), whereas most
of the men (66%) were married. Women were most likely to choose a child as their MC while men were most
likely to choose their spouse; 41% of women chose an MC under 21 compared with only 14% of men. Only 31%
of married women chose their husband, compared with 66% of married men who chose their wife. Qualitative
interviews suggested MCs proved useful for reminding and other supportive tasks in the first three months
but were generally less essential by six months and beyond. Convenience, reliability, and trust were key
considerations in choosing an MC. Children provided the only alternative for many unmarried women, but even
some married women felt children made more reliable MCs than husbands. Participants who had disclosed their
serostatus usually received drug-taking reminders from multiple household members. One participant in the
qualitative sample with poor family relations delayed starting treatment due to unwillingness to identify an MC.
MCs were generally welcome and useful in supporting early adherence. However, disclosure to an MC should not
be a condition of obtaining treatment.
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Introduction
Antiretroviral therapy (ART) is rapidly being scaled
up to meet the needs of patients with HIV, particularly
in Africa. A main feature of some programs is the
requirement or strong suggestion for patients to
choose a ‘‘medicine companion’’ (MC) to provide
support and reminders for ART patients to take their
medications consistently and on schedule (Me´decins
sans frontie`res (MSF), Department of Public Health
of the University of Cape Town, and The Provincial
Administration of the Western Cape. Published by
WHO, Geneva, 2003). Directly observed treatment
for tuberculosis infection (DOTS), theWHO standard
recommended therapy since 1993, usually involves
observation of the dose by a health professional,
despite doubts expressed about the effectiveness and
impact of the direct observation of therapy, (Cox,
Morrow, & Deutschmann, 2008; Davies & Squire,
2008). DOTS usually requires that the patient travel to
a place where the treatment can be observed, whereas
MCs for ART often involve non-health professionals,
typically family members, who support the therapy in
the home setting. More importantly, the MC model
requires an act of disclosure for an illness which is still
highly stigmatized in some settings. There is little
scientific evidence evaluating the demographic and
social characteristics of MCs, how they are chosen,
and whether and for how long they are perceived to be
useful in supporting adherence. This paper reports
on the baseline characteristics of MCs of 1453
Ugandan trial participants receiving ART from an
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nongovernmental organization (NGO) that had a
routine policy of requiring MCs. It also documents
the experience with MCs of a small subset of 40 trial
participants who were interviewed several times over
the first 36 months on ART.
Methods
Methods of the clinical trial have been described in
detail (Amuron et al., 2007). The goal of the trial
was to evaluate the effectiveness as well as the costs
of home-based (HB) ART care as compared with
facility-based (FB) ART care. All ART provision and
services are being carried out by The AIDS Support
Organization (TASO) Clinic in Jinja, southeast
Uganda, in a real-life health care setting. TASO is a
large non-governmental organization with 11 centers
in Uganda offering counseling, out-patient medical
care, and a range of social support services to HIV-
infected patients. TASO also conducts counselor
training, AIDS advocacy and community outreach,
and has been a global pioneer in AIDS care
(Ssebbanja, 2007).
Registration and care are provided for free in this
setting. TASO started providing ART in early 2004
and recruitment of participants into the trial began in
February 2005. Follow-up ended in 2008. Patients
were assessed for eligibility by TASO staff, their
WHO HIV stage was determined, and a CD4 count
and viral load obtained. If CD4 count was below the
eligibility threshold of 200106/l, or their WHO HIV
stage was determined to be late Stage III or IV, they
were offered ART in accordance with Ministry of
Health guidelines. Patients were then randomized to
either HB or FB care, using cluster randomization.
Clusters were defined as geographical areas  a sub-
county, town, village, or part of Jinja town. Forty-
four such areas were defined and randomized in
strata according to the estimated number of HIV-
infected patients and the distance from TASO Jinja.
Patients receiving HB care are visited monthly by a
field officer on a motorcycle who delivers drugs and
monitors the patients using a checklist. Field officers
have mobile phones and can discuss a case with
a physician at TASO if necessary, and determine
whether referral to the clinic is necessary. HB care
patients visit the TASO clinic every six months for a
routine clinical and counseling review. FB patients
visit the clinic every month to collect drugs and be
seen by a nurse; they are assessed routinely every
three months by a counselor and physician. Patients in
both arms can visit the TASO clinic any time they feel
unwell, and they have access to a telephone hotline. In
the FB arm, patients eligible for ART were given
Voluntary Testing and Counseling (VCT) vouchers
for each family member and for the MC, and were
encouraged to bring them to the facility for free VCT.
In the HB arm, ART patients were visited by TASO
field officers and VCT was provided at their homes to
household members and to the MC if requested.
All patients are requested to appoint aMC to assist
them in remembering to take their medicines and to
encourage them when they are not feeling well
(Amuron et al., 2007). MCs were also supposed to
assist by picking up the patient’s drugs if the TASO
team could not reach them in time.Of note, however, is
that direct observation of therapy is not expected of
the MC. In the FB arm, eligible patients were asked to
come along with their MCs on their enrollment visit.
This was a condition for ART initiation. The MCs
were provided with counseling and ART adherence
information on how to support their patients. A flat
fee of UGX 2500 (approximately $1.50) was provided
to compensate their cost of transport. In the HB arm,
patients identified the MCs when the field officers
visited their homes before the enrollment visit. Ad-
herence support information was then given at this
visit. This home visit was a condition for ART
initiation. The MCs of FB patients were interviewed
directly. Information on the MCs of HB patients was
obtained from the patients themselves.
A complementary qualitative study was designed
to chronicle life changes and evolving challenges of
adherence over the first three years on ART using
qualitative methods among a subsample of trial
participants. A subset of 41 patients (21 men and 20
women) were chosen and 40 were interviewed in-depth
at baseline (at the final enrollment visit before patients
had started medication), at three and six months, and
at 36 months after initiation of treatment. One man
was recruited but died soon after recruitment and was
replaced so the final number was 40; not all patients
were available for interview at all rounds. The quali-
tative study sample was stratified to ensure equal
numbers of participants by sex, trial arm, and clinical/
immunological stage contrasting early (CD4 counts
above 150106/l or Stages I and II defining condi-
tions) and advanced (CD4 counts below 100106/l or
Stage III and IV defining conditions) categories. The
patients were asked about the role of their MC, how
they chose their MC, and how helpful the MC was in
their therapy.
Quantitative data were analyzed using Stata v. 9
(Stata Corp., College Station, TX, USA) and Micro-
soft Excel (Microsoft Corp., Redmond, WA, USA).
Textual data on rationales and experiences with MCs
were transcribed, translated, and coded using NVivo
v.7 (QSR International, Melbourne, Australia) and
analyzed by two independent reviewers. This paper
reports on the data collected at baseline on the
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characteristics of MCs in both arms of the study, and
on the qualitative data about MCs collected through
in-depth interviews at baseline, months 3, 6, and 36
(no questions on the MC were asked at the 18th
month interview). Ethical approval was given by the
Uganda National Council of Science and Technol-
ogy, and the Institutional Review Boards of the
Uganda Virus Research Institute, the US Centers
for Disease Control, and the London School of
Hygiene & Tropical Medicine.
Results: baseline characteristics of the patients and of
their chosen ‘‘medicine companion’’ (MC)
Significantly more women (71%) than men (29%)
were recruited into the trial, and both men and
women presented at an advanced stage with very
low median CD4 count and high plasma viral load
(Amuron et al., 2007). Women patients had a mean
age of 36 and men, 40. The mean age of the MCs
chosen is 30.8 years and the median is 30 (33.8 for
men, 29.5 for women, p0.000), but the mode is 14
(Table 1 and Figure 1). The median age of children
under 18 who act as MC was 14 for male patients and
13 for female patients. It is notable that 41.4% of
women chose an MC under 21 compared with only
14% of men. Two of the MCs are reported to be five
years old, and 11% or 160 of MCs are 12 years of age
or under. The majority (75%) of women were either
widowed (51%) or separated or divorced (24%),
whereas most of the men (66%) were married
(Amuron et al., 2007). Only 23% of the women are
currently married, and of these, only 31% chose their
husband as MC, compared with 66% of men who
chose their wife ( p0.000) (Table 1). Women,
including the widowed women, were most likely to
choose a child or other relative or household member.
Of those who were accompanied to TASO, the MC
was the accompanying person in 90% of cases. The
median cost of transport for the accompanying
person was 2000 USh (approximately US$1.15)
(mean of 2888 USh, US$1.65).1 The mean transport
cost reported by patients was 3000 USh, and these
lower transport costs for the MC reflects the fact that
many of the patients have chosen their children as
their MC, and children under about age 12 (or able to
sit on the lap of the adult) benefit from a lower fare
on public or shared private transport.
The occupation of the MCs who accompanied the
(FB) patients (note that about half of the patients 
those in the HB arm  came unaccompanied) are
shown in Table 1. ‘‘Student’’ was the most frequently
reported occupation (31%), again reflecting the
importance of children as MCs, followed by
‘‘farmer’’ (22%), and ‘‘business or self-employed’’
(18%, p0.000).
Patients were asked about the HIV status of their
MC. In most cases (44%) patients reported that they
did not know (or perhaps were not willing to disclose)
the HIV status of their MC. Of those who did report
the status, 15% reported that their MC was HIV
positive, but there were significant differences be-
tween men and women in this regard, with 27% of
men but only 10% of women reporting that their MC
was HIV positive ( pB0.05). Among the married
patients, 55% of wives, and 73% of husbands chosen
as MC were HIV positive. 16% of women and 20%
of men who chose their spouse as MC reported not
knowing that person’s HIV status (Table 1). Thirty
percent of HIV-positive MCs were reported to be on
ART by the patient. Nine of the children under 18
who are MC were reported to be HIV positive by the
patient, and two of them were reported to be on
ART.
Role of the medicine companion (MC) in assisting
patients with adherence: data from qualitative
interviews
At baseline patients gave a variety of reasons for their
choice of MC, including that he/she would give
financial support; that person would help with house
chores, e.g., cooking, washing, etc.; the person would
always be around when needed or was someone they
lived with; the person was also on antiretroviral drugs
and/or was a TASO patient and so could easily
remember; and finally, that the person cared about
their well-being.
As noted above, most of the men chose their wife,
and one male patient’s response about how he chose
his wife as hisMC is typical of the reactions of the men
in particular: ‘‘She is the one I stay with and besides,
she is also on drugs and she too chose me as her
medicine companion, so, each reminds the other.’’ On
the other hand, women tended to choose their children
or other immediate family like their mother, father,
sister, nephew, or aunt. Since many of the women are
widowed, separated, or divorced, the children were the
people they lived with. They claimed that children
were home most of the time; they could be trusted and
also they cared about the health of their mother.
Respondents did not mention any concerns or dis-
comfort about having children as their MCs, or any
misgivings about the responsibility they were entrust-
ing to their children. One woman responded as
follows: ‘‘My mother is now old; I can’t trust my
brother more than the kids. Even his wife . . . You
never know, he could also be sick and [she could]
decide to steal the what, the drugs.’’ Another woman
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noted that ‘‘As she is a child, she feels obliged and
concern for her mother and so has to remind me.’’ One
male respondent also chose his son: ‘‘I live with my
children in the same house and the elder son is in
senior four, I wanted him to know the problems he
would face in case I died at this moment now that he is
the first-born child.’’
Only one woman in the sub-sample had a problem
with disclosing her status, claiming that she didn’t
trust anyone, even her family. She refused to present
an MC and neither did she allow TASO officers to
visit her home as was required for all HB patients
Table 1. Characteristics of medicine companions of patients on antiretroviral therapy.
Men Women All
Choice of medicine companion: all patients, n1453
Spouse/partner 186 (44) 75 (7) 261 (18) PB0.001
Biological child 64 (15) 409 (40) 473 (33)
Other relative/HH member 154 (37) 497 (48) 651 (45)
Neighbor/friend 14 (3) 47 (5) 61 (4)
Other 4 (1) 3 (0) 7 (0)
Total 422 1031 1453
Age of medicine companion: all patients, n1453
Under 21 60 (14) 427 (41) 487 (33) PB0.001
2130 127 (30) 175 (17) 302 (21)
3140 137 (33) 168 (16) 305 (21)
4150 43 (10) 134 (13) 177 (12)
5165 31 (7) 67 (7) 98 (7)
Over 65 10 (2) 36 (3) 46 (3)
Missing 14 (3) 24 (2) 38 (3)
Occupation of medicine companion: n750a
Business/self employed 50 (23) 84 (16) 134 (18) PB0.001
Professional 26 (12) 39 (7) 65 (9)
Student 35 (16) 200 (38) 235 (31)
Farmer 60 (27) 106 (20) 166 (22)
Unemployed 17 (8) 63 (12) 80 (11)
Housewife 30 (14) 22 (4) 52 (7)
Other 1 (0) 17 (3) 18 (2)
HIV serostatus of medicine companionb: all patients, n1453
Positive 112 (27) 103 (10) 215 (15) PB0.001
Negative 144 (34) 457 (44) 601 (41)
Don’t know 165 (39) 472 (46) 637 (44)
Choice of medicine companion among married patients: n516
Spouse/partner 185 (66) 73 (31) 258 (50) PB0.001
Biological child 32 (11) 85 (36) 117 (23)
Other relative/HH member 55 (20) 64 (27) 119 (23)
Neighbor/friend 5 (2) 15 (6) 20 (4)
Other 2 (1) 0 (0) 2 (0)
aIt includes only medicine companions of facility-based patients who accompanied patients to TASO.
bIt is as reported by patient.
0 20 40 60 80
Medicine companion age
Female
Male
Figure 1. Age of medicine companions chosen, by gender
of patient.
38 S.D. Foster et al.
before they were started on drugs. This delayed her
getting on ART and she started a month later, but
this was after she had been convinced by the
counselor who was following her up to choose an
MC, and to be visited at home. She described the
situation as follows: ‘‘I don’t have any one, I am
alone. And I even told [her counselor] that I keep my
things to myself and if I hadn’t thought that I could
reach a time whereby I couldn’t manage on my own
[if I thought I could continue to manage by myself],
I wouldn’t have told that niece. They would have
known about it from the documents that I had HIV/
AIDS and was getting treatment at TASO. Now that
I never had children, my relatives turned against me
and isolated me and it was after seeing that I had
acquired property [riches] that they wanted to come
back to me but I had already had enough.’’
At three months, 29 patients were again inter-
viewed (at this round, only 29 were interviewed
because four had died, and eight weren’t interviewed
for other reasons), and most still felt they needed the
support of their MCs. One man whose wife (his MC)
had left him was asked ‘‘How do you manage now
that you don’t have a medicine companion?’’ He
responded that ‘‘I am now depending on the watch
alone to remind me, it’s what I look at and know that
it’s time for taking drugs.’’
At six months, 36 patients were interviewed, and
by this time most said they had become used to taking
the drugs and thus could manage on their own even
without this MC, and that the MC was only necessary
in the early stages of ART when they were becoming
used to the drugs and were still weak and had more
illnesses. Some MCs continued to do their work
though some patients felt that it was not very
necessary as the drug companion could also forget.
Drug taking had become routine for them: ‘‘Eeh, how
would I forget my life, ah, and wait to be reminded!’’
In contrast, one female patient was lonely and
missed having an MC (her mother), and said ‘‘I have
faced many problems and it is the reason why I
sometimes miss my drugs because I have no one to
tell my needs yet she was there before and she could
plan what to eat. I now sit back and think of what to
do in vain, and by the time I realize, the time for drug
taking has already gone.’’
At 36 months, 33 patients were interviewed at the
final round. By this time, dependency on MCs had
greatly reduced and all but one said they were very
used to taking their drugs and so could manage on
their own. Most of the men, even those who weren’t
married, said a ‘‘wife’’ would make the best drug
companion ‘‘because you are together all the time, she
is the one that takes care of you and she knows your
health.’’ Women on the other hand said children were
best, because they cared and were home most of the
time. Only 3 of the 16 women who were interviewed
at the final round said a spouse would make the ideal
MC. By this time many of the household members or
family had become involved in the role of reminding
the patient to take their medicines. One patient
commented as follows:
Even my sister in-law reminds me and even her
husband, and besides, there is a radio at home [to
indicate the time]. All the children here know about it
and they also tell me when they see that it’s time [for
taking drugs], ‘‘take your drugs Aunt.’’ There is one
who is six years but she tells me ‘‘don’t forget the
drugs, Aunt.’’
Sometimes the situation involves multiple family
members. One woman was initially staying with her
father who is her MC. At the six month follow-up
visit, she had rented a room about 300 meters from
the father. She had a new partner and one day she
found him examining the drugs, and she snatched
them from him and ran out with them. Her maternal
aunt who lived next door advised her not to store the
drugs in the house again but keep them at the aunt’s
place, and that is where she goes to take the drugs.
Her father still stores the drugs; he gives her drugs for
few days and refills her stocks whenever they get
finished. So her drugs are kept by two people  her
father who replenishes them regularly, and her aunt
who lives next door.
Discussion
The main rationale for requiring an MC  which thus
entails disclosure of one’s HIV status  was that the
support provided by the MC would lead to improved
adherence. This study did not measure the impact of
the MC on outcomes (all patients had MCs), but it
nonetheless documents the main characteristics and
changing role of the MCs as the patients got
accustomed to being on lifelong ART. Unlike some
other programs (Behforouz, Farmer, & Mukherjee,
2004; Farmer et al., 2001), direct observation of
therapy was not stressed in this model of support.
There are many factors which can affect adherence;
a study on 304 patients of three programs in Uganda
(Byakika-Tusiime et al., 2005) found that ‘‘Age,
gender, education, religions, treatment duration,
dosing interval, pill burden, drug and alcohol con-
sumption, confidence in ART, distance from treat-
ment centre, cost of medications, depression, social
support and number of concurrent conditions did not
predict adherence.’’ The main predictor of adherence
in their study was shortage of drugs due to lack
of money. Fear of disclosure has been identified as
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a major barrier to adherence (Mills et al., 2006).
External factors can also play an important role in
adherence; in one Ugandan study, 1.2% of patients
became convinced by religious authorities that they
had been ‘‘spiritually healed’’ and discontinued their
therapy (Wanyama et al., 2007).
Somewhat surprisingly, only one other similar
program was found in the literature in which the
patients themselves select an MC  the Khayelitsha
program in South Africa, which requires patients to
choose, and disclose their HIV status, to a ‘‘treatment
assistant.’’ They describe the process as follows:
‘‘After the patient has been counselled about ARV
treatment, a clinic worker assesses the social and
support structures available by conducting a home
visit. The home visit also verifies the person’s family
environment and disclosure to at least one person
who will act as a treatment assistant’’ (Me`decins sans
frontie´res (MSF) et al., 2003). That person ‘‘is usually
someone living in the household, aware of the
person’s status and willing to assist with medication
as necessary.’’ No mention is made of specifically
observing therapy.
In two other cases, programs focus on directly
observed therapy and assign a person to assist the
patient in taking their medicines. In Haiti, a program
of ART provision relied heavily on ‘‘accompagna-
teurs,’’ community health promoters, but these were
appointed by the health staff rather than chosen by
the patients themselves. Their role was to ‘‘accom-
pany’’ the patients by directly observing therapy and
providing other types of assistance (Farmer et al.,
2001). Another study examined the feasibility of
integrating ART into the tuberculosis DOT pro-
gramme (Friedland et al., 2004), and refers to the
need for ‘‘treatment supporters’’ who are appointed
by the health services rather than chosen by the
patient.
Adherence and outcomes in this group of TRIAL
patients were very good in comparison with other
studies. Although the study was carried out within a
normal resource-constrained health service setting
(Amuron et al., 2007), the mortality rates of about
six deaths per 100-person-years and virologic failure
rates of about eight per 100-person-years were better
than those reported from most other settings (Jaffar
et al., 2009). Others have reported mortality rates
ranging between 6 and 15 deaths per 100-person years
(Coetzee et al., 2004; Etard et al., 2006; Ferradini
et al., 2006; Marazzi et al., 2008; Mermin et al., 2008;
Stringer et al., 2006; Toure et al., 2008) and virologic
failure from 15 to 40% (Braitstein et al., 2006;
Coetzee et al., 2004; Fielding et al., 2008; Laurent
et al., 2002; Vicente et al., 2006). However, some
caution as to the possible role played by the MC in
achieving these results is warranted; since virtually all
patients had MCs it is not possible to distinguish
between those who had and those who did not have
MCs in achieving these outcomes. Other factors such
as the intensive counseling and support provided by
TASO staff might have also been important in these
outcomes.
There were differences between men and women in
terms of who they chose as their MC, and why. In
many ART programs in sub-Saharan Africa, there are
many more women than men among patients on ART
therapy; in this trial, 71% of the patients were women.
Only 25% of these women were married, as compared
with 66% of the men. Married men were more than
twice as likely to choose their wife as MC as married
women (66% vs 31%), and in both cases the spouse
who was chosen as MC was likely to be HIV positive
(55% of wives, and 73% of husbands chosen as MC
were HIV positive). It seems likely that some of the
married women did not choose their husband as MC
because they had not yet disclosed their status to their
husband and were comfortable with choosing hus-
bands as MC only if the husband already knew the
woman’s HIV status. Disclosure of HIV status to
the husband or partner in Uganda and elsewhere in
Africa often has particularly severe consequences for
women, including domestic violence, abandonment,
and divorce (Karamagi, Tumwine, Tylleskar, &
Heggenhougen, 2006; Koenig et al., 2003). For the
men, if they did not have a spouse to whom they were
willing to disclose, the idea of being required to disclose
their status to another relative or friendmay have been
a deterrent (as evidenced by the small percentage of
men (29%) in the trial) to obtaining care at TASO
where disclosure is strongly promoted, and may be
interpreted by some as essentially mandatory. There
are other sources of ART in Jinja which do not require
or strongly encourage disclosure. Men may also have
chosen their wives knowing that culturally the expec-
tation is that a woman has a duty to look after her
husband, no matter what. Women on the other hand
seem to have more confidence in their children than in
their husband in terms of whowould look after them in
their illness, rather than punish them for disclosing
their HIV status. Hardon et al. (2007) found in a study
of ART adherence in three African countries (includ-
ing Uganda) that in all three, children were involved in
reminding patients to take their medicines and they
recommend that ‘‘adherence support could recognize
the potential role of children . . . and provide them
with adequate information on ART . . . to empower
them in their role as treatment supporters’’ (Hardon
et al., 2007).
The relationship between anMC and patient is one
of mutual obligation; Ware et al. (2009) explain that
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the ‘‘social expectations of adherence create obliga-
tions on the part of patients, who must meet these
expectations to preserve relationships with helpers.’’
Adherence ‘‘allows patients to meet social responsi-
bilities by preventing health decline and reducing the
need for support’’(Ware et al., 2009). They explain that
the ‘‘social expectations of adherence create obliga-
tions on the part of patients, who must meet these
expectations to preserve relationships with helpers’’
(Ware et al., 2009). Adherence ‘‘allows patients tomeet
social responsibilities by preventing health decline and
reducing the need for support’’ (Ware et al., 2009).
In this study patients found the MC to be very
useful at the beginning of the treatment, but as time
passed they became more autonomous and relied less
on their MC. In a South African study, one female
patient complained ‘‘my treatment supporter is over-
whelming me . . . I needed him when I was very
sick . . . but now I am feeling well and I need him to
back off a little bit . . . to give me some space so I can
be in charge with my life again’’ (Nachega et al., 2006).
The requirement to choose an MC raises a
number of important questions, especially regarding
what might be termed the ‘‘the culture of disclosure.’’
In this group, only 41 (3%) of participants refused to
join, or left the trial early, due to stigma (Jaffar et al.,
2009); however, the group might be comprised
primarily of those who had opted to seek care at
TASO despite knowing that disclosure of their HIV
status would be expected of them. If the support
provided by an MC is valuable to some patients, it
comes with an important trade-off  the loss of
confidentiality and autonomy for the patient. Doubts
about the advisability of requiring disclosure to an
MC or other individual have been expressed by a
number of authors. Liechty and Bangsberg (2003)
observe that ‘‘the program [in Haiti] has demon-
strated remarkable success. However, it is impossible
to know how much of the effect is due to the merits of
community driven and supportive healthcare, stable
medication supply and distribution, the medication
alone, or witnessed dosing’’ (Liechty & Bangsberg,
2003). They stress that ‘‘witnessed dosing of HIV
antiretroviral therapy is complicated by the need for
lifelong treatment, daily medication dosing, and the
consequent impact on individual rights in the setting
of a highly stigmatizing disease.’’ Finally, they note
that ‘‘we still must face the question of why calls
for directly observed HIV therapy are limited to
sub-Saharan Africa, and not North America or
Western Europe’’ (Liechty & Bangsberg, 2003). A
study involving focus groups with rural American
HIV patients noted that ‘‘Some participants . . .
appeared to be more willing to risk their health
than risk people learning of their medical condition’’
(Whetten-Goldstein, Nguyen, & Sugarman, 2001).
Could this be the case with certain categories of
HIV-positive African patients as well? Disclosure can
lead to stigma, and ‘‘stigma is feared because it leads
to social isolation, undermining relationships that are
essential to survival’’ (Ware et al., 2009).
Conclusions
This paper has tried to answer the basic question of
who is chosen as an MC in this Ugandan setting, and
how useful they are perceived to be by the patients,
while raising a number of additional questions. What
is the role of the MC, and how well do they under-
stand this role? How well prepared are they to support
the lifelong therapy of the patient? If the patient fails
therapy, will the MC feel that they have failed the
patient? Will they be blamed by the patient or some-
one else in the family? What of the responsibility given
to a child who is designated as an MC by his or her
parent? What is the role and importance of disclosure
of HIV status in successful adherence? Perhaps most
importantly, is the requirement of disclosure discoura-
ging many who need and are eligible for ART, men in
particular, from coming forward?
Our study supports the notion that treatment
companions are useful at the start of treatment, but
also that after a while, most people no longer need
them. Living in a supportive home environment where
everyone knows the person’s HIV status, and reminds
them to take their medicines, may be the optimal form
of support for adherence. But disclosure and selection
of an MC should be encouraged  not required 
because it does mandate an act of disclosure and
may delay some people from getting on treatment,
both of which may raise ethical concerns, especially in
a model where the level of support offered to patients
might be less than that provided to TASO patients.
These considerations should form the basis for addi-
tional research before the model of requiring the
selection of an medicine companion is adopted as a
standard for ART programs around Africa.
Note
1. These amounts can be compared with the monthly
incomes reported by patients of 15,000 USh for women
and 20,000 USh for men, or approximately US$8.60 and
US$11.50, respectively.
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